Back to Journals » OncoTargets and Therapy » Volume 10

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Total article views   Abstract views HTML views PDF downloads Totals
4,165 Dovepress* 2,697 949+ 922 3,646
PubMed Central* 0 519 190 519
Totals 2,697 1,468 1,112 4,165
*Since 6 January 2017
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed Central and Google Scholar